 Induction sustained patency clot-selective coronary thrombolysis Hybrid-B plasminogen activator prolonged biological half-life BACKGROUND utility tissue-type plasminogen activator t-PA coronary thrombolysis early reocclusion problem anticoagulation patients successful recanalization study utility Hybrid-B molecular variant t-PA prolonged half-life circulation coronary thrombolysis patency presence thrombogenic stimulus METHODS RESULTS intact anesthetized dogs mg Hybrid-B minutes mg t-PA Activase minutes minutes left anterior coronary artery occlusion thrombogenic copper coil Time averaged SD minutes minutes Hybrid-B t-PA NS Hybrid-B bolus mg minute high initial concentration blood time lysis minutes Dogs Hybrid-B infusion bolus prolonged time reocclusion minutes minutes dogs t-PA maintenance subthrombolytic active concentration activator blood persistence Hybrid-B blood concentrations fibrinogen alpha control values CONCLUSIONS Thus Hybrid-B novel variant t-PA unique pharmacokinetic properties elicits clot-selective coronary thrombolysis